Century Therapeutics, Inc. Pre-Tax Income
Century Therapeutics, Inc. (IPSC) reported Pre-Tax Income of -$9.65 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-03-12
- Century Therapeutics, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was -$19.24M.
- Century Therapeutics, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was -$34.42M.
- Century Therapeutics, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-06-30 was -$32.54M.
- Century Therapeutics, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-03-31 was $76.56M.
- Century Therapeutics, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$9.65M.
- Century Therapeutics, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$124.78M.
- Century Therapeutics, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$134.79M.
- Century Therapeutics, Inc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was -$130.84M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$19.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$53.66M derived: sum of 2 quarters · filed 2026-03-12 | -$86.20M derived: sum of 3 quarters · filed 2026-03-12 | -$9.65M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$34.42M 10-Q · filed 2025-11-13 | -$66.96M derived: sum of 2 quarters · filed 2025-11-13 | $9.59M 10-Q · filed 2025-11-13 | -$24.70M derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-06-30 | -$32.54M 10-Q · filed 2025-08-14 | $44.02M 10-Q · filed 2025-08-14 | $9.72M derived: sum of 3 quarters · filed 2026-03-12 | -$21.51M derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-03-31 | $76.56M 10-Q · filed 2025-05-15 | $42.26M derived: sum of 2 quarters · filed 2026-03-12 | $11.03M derived: sum of 3 quarters · filed 2026-03-12 | -$20.16M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-12-31 | -$34.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$65.53M derived: sum of 2 quarters · filed 2026-03-12 | -$96.72M derived: sum of 3 quarters · filed 2026-03-12 | -$124.78M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$31.23M 10-Q · filed 2025-11-13 | -$62.42M derived: sum of 2 quarters · filed 2025-11-13 | -$90.48M 10-Q · filed 2025-11-13 | -$130.75M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$31.18M 10-Q · filed 2025-08-14 | -$59.25M 10-Q · filed 2025-08-14 | -$99.51M derived: sum of 3 quarters · filed 2025-08-14 | -$131.64M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$28.06M 10-Q · filed 2025-05-15 | -$68.33M derived: sum of 2 quarters · filed 2025-05-15 | -$100.46M derived: sum of 3 quarters · filed 2025-05-15 | -$132.80M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$40.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | -$72.39M derived: sum of 2 quarters · filed 2025-03-19 | -$104.74M derived: sum of 3 quarters · filed 2025-03-19 | -$134.79M 10-K · filed 2025-03-19 |
| 2023-09-30 | -$32.13M 10-Q · filed 2024-11-05 | -$64.47M derived: sum of 2 quarters · filed 2024-11-05 | -$94.53M 10-Q · filed 2024-11-05 | -$126.17M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$32.34M 10-Q · filed 2024-08-08 | -$62.40M 10-Q · filed 2024-08-08 | -$94.05M derived: sum of 3 quarters · filed 2024-08-08 | -$124.77M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$30.06M 10-Q · filed 2024-05-09 | -$61.71M derived: sum of 2 quarters · filed 2024-05-09 | -$92.43M derived: sum of 3 quarters · filed 2024-05-09 | -$123.40M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$31.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$62.37M derived: sum of 2 quarters · filed 2024-03-14 | -$93.34M derived: sum of 3 quarters · filed 2024-03-14 | -$130.84M 10-K · filed 2024-03-14 |
| 2022-09-30 | -$30.72M 10-Q · filed 2023-11-09 | -$61.69M derived: sum of 2 quarters · filed 2023-11-09 | -$99.19M 10-Q · filed 2023-11-09 | -$127.34M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$30.97M 10-Q · filed 2023-08-09 | -$68.47M 10-Q · filed 2023-08-09 | -$96.62M derived: sum of 3 quarters · filed 2023-08-09 | -$122.63M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$37.50M 10-Q · filed 2023-05-11 | -$65.65M derived: sum of 2 quarters · filed 2023-05-11 | -$91.66M derived: sum of 3 quarters · filed 2023-05-11 | -$114.93M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$28.15M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$54.16M derived: sum of 2 quarters · filed 2023-03-16 | -$77.43M derived: sum of 3 quarters · filed 2023-03-16 | -$95.78M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$26.01M 10-Q · filed 2022-11-10 | -$49.28M derived: sum of 2 quarters · filed 2022-11-10 | -$67.63M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$23.27M 10-Q · filed 2022-08-11 | -$41.62M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$18.35M 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | -$53.58M 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |